Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age.
TGFbeta is involved in the response to DNA damage and signaling the cell cycle checkpoint response, in large part achieved by modulating the activity of the ATM kinase. We have investigated if the presence of a common polymorphism in the TGFbeta receptor TGFBR1 might impact genomic instability in human colorectal cancer. In order to obtain statistically significant numbers of patients with the lesser polymorphism, 177 colorectal cancer patients were genotyped for either the major form of the TGFBR1 receptor gene, homozygous for an internal segment of 9 alanines (9A/9A), or the lesser form, heterozygous for the polymorphism containing 6 alanines (9A/6A). Intrachromosomal genomic instability in the tumors was then quantified by the robust inter-(simple sequence repeat) PCR method. Tumors from all 26 patients heterozygous with the (9A/6A) polymorphism in TGFBR1 exhibited significantly lower genomic instability than from a randomly selected set [the first identified] of 37 patients with the (9A/9A) polymorphism (p=0.0002, Mann-Whitney). The median age of onset for the (9A/6A) patients was 70 years, compared with a median age of onset of 63 years for the patients carrying the (9A/9A) form (p=0.031, Mann-Whitney). These results are consistent with the model wherein genomic instability facilitates tumor progression, with lesser instability associated with later disease presentation. Clinically, our findings may be developed into improved screening guidelines with respect to the age at which colonoscopy is initiated in carriers of the TGFBR1*6A allele.
Dutt
Smitha S
SS
Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Chen
Neng
N
Darbary
Huferesh K
HK
Swede
Helen
H
Petrelli
Nicholas J
NJ
Stoler
Daniel L
DL
Anderson
Garth R
GR
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D001483:Base Sequence; D015179:Colorectal Neoplasms / Q000235:genetics*; D004249:DNA Damage; D017931:DNA Primers / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D042822:Genomic Instability; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D018598:Minisatellite Repeats; D011110:Polymorphism, Genetic; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D015398:Signal Transduction / Q000235:genetics
D017931:DNA Primers; D004273:DNA, Neoplasm; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077293:Receptor, Transforming Growth Factor-beta Type I; C000625841:TGFBR1 protein, human
J Thorac Oncol. 2007 Jul;2(7):657-9
17607123
Cancer Res. 2001 Nov 15;61(22):8274-83
11719460
Science. 2005 Oct 7;310(5745):68-71
16210527
Science. 2006 Oct 13;314(5797):268-74
16959974
Oncol Res. 2005;15(4):233-8
17822283
Oncogene. 2005 Jul 14;24(30):4861-6
15897900
J Clin Oncol. 2005 May 1;23(13):3074-8
15860866
Cell. 2000 Jan 7;100(1):57-70
10647931
Cancer Genet Cytogenet. 2006 Jul 15;168(2):98-104
16843098
Br J Cancer. 2007 Oct 22;97(8):1175-9
17848956
Genes Chromosomes Cancer. 1997 Jan;18(1):19-29
8993977
Gastroenterology. 2003 Feb;124(2):544-60
12557158
Science. 1998 May 15;280(5366):1086-8
9582123
Cancer Res. 1999 Nov 15;59(22):5678-82
10582683
Science. 1995 Jun 2;268(5215):1336-8
7761852
JAMA. 2005 Oct 5;294(13):1634-46
16204663
Nat Genet. 2001 Oct;29(2):117-29
11586292
Cancer Res. 2006 Nov 15;66(22):10861-9
17090522
Mutat Res. 2004 Dec 21;568(2):283-92
15542115
Bioessays. 2001 Nov;23(11):1037-46
11746220
Int J Cancer. 1999 Jul 2;82(1):43-51
10360819
Cancer Res. 2001 Nov 15;61(22):8351-2
11719470
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42
17108085
Cancer Res. 1998 Jul 1;58(13):2727-32
9661882
Nat Rev Cancer. 2003 Mar;3(3):155-68
12612651
Ann Surg Oncol. 2002 Nov;9(9):901-6
12417513
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15121-6
10611348
J Clin Oncol. 2005 Oct 20;23(30):7743-4; author reply 7744-6
16234535
Clin Cancer Res. 2007 Jun 15;13(12):3748-52
17575241